 |
85 Diseases |  |
26 Trials |
|
26 Trials |  |
4609 News |  |
| «12345678910111213...5758» |
- | Soliris (eculizumab) / AstraZeneca
Journal: Comparison of Intermolecular Halogen...Halogen Distances in Organic and Organometallic Crystals. (Pubmed Central) - Aug 16, 2023
In particular, it was found that, for the Hg-Hal groups (Hal = Cl, Br, I), there is a high probability that the crystals have Hg-Hal...Hal-Hg distances with length ? R.
- cemdisiran (ALN-CC5) / Alnylam, Regeneron, Veopoz (pozelimab) / Regeneron
Trial completion date, Trial termination, Trial primary completion date, Combination therapy: ACCESS 2: Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (clinicaltrials.gov) - Aug 16, 2023
P3, N=2, Terminated, Sponsor: Regeneron Pharmaceuticals
R. Trial completion date: Sep 2026 --> Jul 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2025 --> Jul 2023; Sponsor decision not related to efficacy or safety.
- || Review, Journal: Biologic drugs in the treatment of juvenile dermatomyositis: a literature review. (Pubmed Central) - Aug 15, 2023
The most frequently used biologic drugs were rituximab (RTX, 50%) and tumor necrosis factor (TNF) inhibitors (34.8%). In a few cases, abatacept (4.3%), anti-interleukin-1 agents (0.9%), tocilizumab (0.9%), bortezomib (0.4%), ustekinumab (0.2%), eculizumab (0.2%), and golimumab (0.2%) were used...Infliximab was most frequently preferred in calcinosis (43.3%), while adalimumab in skin involvement (50%) and etanercept in resistant/recurrent diseases (80%)...
- || Soliris (eculizumab) / AstraZeneca
Review, Journal: New findings in preventing recurrence and improving renal function in AHUS patients after renal transplantation treated with eculizumab: a systemic review and meta-analyses. (Pubmed Central) - Aug 15, 2023
In a few cases, abatacept (4.3%), anti-interleukin-1 agents (0.9%), tocilizumab (0.9%), bortezomib (0.4%), ustekinumab (0.2%), eculizumab (0.2%), and golimumab (0.2%) were used...Infliximab was most frequently preferred in calcinosis (43.3%), while adalimumab in skin involvement (50%) and etanercept in resistant/recurrent diseases (80%)... Furthermore, the drug was effective in improving platelet counts (
- | Soliris (eculizumab) / AstraZeneca, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Journal: Focused Jurisdictional Scan of Glomerulonephritis Medication Access in Canada: A Program Report. (Pubmed Central) - Aug 15, 2023
Interprovincial differences in the drugs funded, funding criteria, and application process may affect timely and equitable access to GN medications across Canada. Given the rarity of GN, a pan-Canadian funding approach may be warranted to improve the current state.
- | Journal: Advancements in Targeted Therapies for Generalized Acetylcholine Receptor Antibody Positive Myasthenia Gravis: Beginnings of a Paradigm Shift. (Pubmed Central) - Aug 14, 2023
Compared to traditional immune modulatory therapies (steroids, non-steroidal immunosuppressive agents), these agents have more specific target engagement via inhibition of complement activation (eculizumab, ravulizumab, zilucoplan) or blockade of IgG recycling via the neonatal Fc receptor (FcRn; efgartigimod, rozanolixizumab)...B-cell targeting with rituximab was safe and well-tolerated but with less impressive efficacy in two phase 2 studies...A paradigm shift is afoot. The challenge is figuring out where these therapies may fit in gMG treatment algorithms.
- || Soliris (eculizumab) / AstraZeneca, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Review, Journal: Antiphospholipid Syndrome: State of the Art of Clinical Management. (Pubmed Central) - Aug 12, 2023
Finally, it has been observed that SARS COV2 infection may produce vascular complications mimicking the clinical and pathophysiological features of APS and particularly of CAPS. From this point of view, attention has been focused on the "protective" role of anticoagulant therapy in preventing thrombotic complication when these clinical conditions coexist.
- | Soliris (eculizumab) / AstraZeneca
Journal: Polycythemia as an Uncommon Finding in 2 Children, One With Systemic Capillary Leak Syndrome and the Other With Protein-losing Enteropathy Caused by CD55 Deficiency. (Pubmed Central) - Aug 11, 2023
We present a 10-year-old girl with hypoalbuminemia, polycythemia, and edema who died as a result of an SCLS attack and a 1-year-old girl with PLE who was successfully treated with eculizumab. Our experience suggests that hematologists should be alert for SCLS and PLE in children with relative polycythemia.
- || Soliris (eculizumab) / AstraZeneca
Review, Journal: Atypical Hemolytic-Uremic Syndrome: Genetic Basis, Clinical Manifestations, and a Multidisciplinary Approach to Management. (Pubmed Central) - Aug 10, 2023
Adequate screening is required to monitor for sequelae. First-line treatment is the monoclonal antibody eculizumab, but several organ systems may require specialized interventions and coordination of care with sub-specialists.
- | Soliris (eculizumab) / AstraZeneca
Journal: Atypical hemolytic and uremic syndrome in Algeria: diagnostic difficulties and therapeutic constraints (Pubmed Central) - Aug 9, 2023
Six patients received eculizumab, with an average age of 3.6 years...At 2 years of evolution, out of 7 children having reached this stage, five had renal sequelae and four of them had CKD. The severe prognosis of this disease makes early diagnosis and treatment essential.
- |||||| Voydeya (danicopan) / AstraZeneca, Soliris (eculizumab) / AstraZeneca, Ultomiris (ravulizumab-cwvz) / AstraZeneca
New trial: Danicopan Early Access Program (clinicaltrials.gov) - Aug 9, 2023
P=N/A, N=0, Available, Sponsor: Alexion
- || Soliris (eculizumab) / AstraZeneca
Review, Journal, PD(L)-1 Biomarker, IO biomarker: Antibody-mediated rejection in xenotransplantation: Can it be prevented or reversed? (Pubmed Central) - Aug 7, 2023
Potential therapies include (i) inhibition of complement activation (e.g., by IVIg, C1 INH, or an anti-C5 antibody), but some complement inhibitors are not effective in NHPs, for example, eculizumab...We suggest that treatment with a systemic complement inhibitor is likely to be most effective, possibly combined with anti-inflammatory agents (if these are not already being administered). Ultimately, it may require further genetic engineering of the organ-source pig to resolve the problem entirely, for example, knockout or knockdown of SLA, and/or expression of PD-L1, HLA E, and/or HLA-G.
- | Soliris (eculizumab) / AstraZeneca, Ultomiris IV (ravulizumab-cwvz IV) / AstraZeneca
Journal, HEOR, Real-world evidence, Cost of care, Real-world: Descriptive, real-world treatment patterns, resource use, and total cost of care among eculizumab- and ravulizumab-treated members with paroxysmal nocturnal hemoglobinuria. (Pubmed Central) - Aug 7, 2023
Dr Burke reports employment by Prime Therapeutics, LLC, which has received research funding from Apellis Pharmaceuticals. Dr Gleason reports employment by Prime Therapeutics, LLC, which has received research funding from Apellis Pharmaceuticals; serves on the advisory committee at the Institute for Clinical and Economic Review; and has served on the Board of Directors at the Academy of Managed Care Pharmacy.
- || Review, Journal: Molecular pharmacology in complement-mediated hemolytic disorders. (Pubmed Central) - Aug 7, 2023
Finally, aHUS is an indication for complement inhibitors. Eculizumab and ravulizumab have been approved, whilst other C5 inhibitors, and novel lectin pathway inhibitors are under active investigation in this disease.
- | Soliris (eculizumab) / AstraZeneca
Journal: Biochemical phenotyping of paroxysmal nocturnal hemoglobinuria reveals solute carriers and ?-oxidation deficiencies. (Pubmed Central) - Aug 5, 2023
We demonstrated significant differences in the metabolomes of the PNH patients compared to healthy controls. Eculizumab infusion seemed to improve deficiencies in the acyl CoA metabolism and may have a role in the mitochondrial oxidative process of long and medium-chain fatty acids, reducing oxidative stress, and inflammation.
- ||| Soliris (eculizumab) / AstraZeneca
Enrollment open: Soliris: Eculizumab in Pediatric and Adult Participants With Atypical Hemolytic Uremic Syndrome (aHUS) in China (clinicaltrials.gov) - Aug 4, 2023
P=N/A, N=25, Recruiting, Sponsor: Alexion
Eculizumab infusion seemed to improve deficiencies in the acyl CoA metabolism and may have a role in the mitochondrial oxidative process of long and medium-chain fatty acids, reducing oxidative stress, and inflammation. Not yet recruiting --> Recruiting
- THE SILENT CULPRIT: PAROXYSMAL NOCTURNAL HEMOGLOBINURIA MASQUERADING AS CRYPTOGENIC STROKE (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_5142;
- ATYPICAL HUS IN THE ICU (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_3524;
- DON'T FORGET THE LUNGS: A CASE REPORT OF ATYPICAL HEMOLYTIC UREMIC SYNDROME INDUCING PULMONARY AND DIFFUSE ALVEOLAR HEMORRHAGE (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_3420;
- SEVERE HYPERHEMOLYSIS SYNDROME IN SICKLE CELL ANEMIA (Convention Center Exhibit Hall - Rapid Area 1C) - Aug 4, 2023 - Abstract #CHEST2023CHEST_3158;
- A CASE OF ATYPICAL HEMOLYSIS UREMIC SYNDROME (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_3082;
- A CASE OF FATAL THROMBOTIC MICROANGIOPATHY AND ACUTE PANCREATITIS DUE TO COXSACKIE B4 INFECTION (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_3038;
- SHIGA TOXIN-ASSOCIATED HEMOLYTIC UREMIC SYNDROME WITH SEVERE NEUROLOGIC MANIFESTATIONS RESULTING IN MULTI-ORGAN FAILURE AND DEATH (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_3031;
- DIAGNOSTIC CHALLENGE: AN UNFORTUNATE AND RARE CASE OF POSTPARTUM COEXISTING DISSEMINATED INTRAVASCULAR COAGULATION AND COMPLEMENT-MEDIATED THROMBOTIC MICROANGIOPATHY (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_1195;
- | Soliris (eculizumab) / AstraZeneca
Journal: Eculizumab as a promising rescue therapy for acute exacerbations of myasthenia gravis. (Pubmed Central) - Aug 3, 2023
Not yet recruiting --> Recruiting No abstract available
- Soliris (eculizumab) / AstraZeneca
Case Report of Paroxysmal Nocturnal Hemoglobinuria and Small Intestinal Ulcers: A Rare Finding With Common GI Symptoms (Exhibit Hall) - Jul 29, 2023 - Abstract #ACG2023ACG_1733;
Treatment options include blood transfusions, iron supplementation, and targeted therapy such as eculizumab, which inhibits the complement system. To manage GI ulcers, proton pump inhibitors (PPIs) or H2 blockers may also be prescribed.
- || Soliris (eculizumab) / AstraZeneca
P4 data, Journal, Real-world evidence, Real-world: Real-world safety profile of eculizumab in patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, or generalized myasthenia gravis: an integrated analysis of post-marketing surveillance in Japan. (Pubmed Central) - Jul 29, 2023
To manage GI ulcers, proton pump inhibitors (PPIs) or H2 blockers may also be prescribed. This is the largest safety dataset on eculizumab in Japan derived from more than 10
- | Soliris (eculizumab) / AstraZeneca, Ultomiris IV (ravulizumab-cwvz IV) / AstraZeneca
Journal, HEOR: Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome. (Pubmed Central) - Jul 29, 2023
Adult patients and caregivers of pediatric patients indicated an overall preference for ravulizumab than eculizumab for the treatment of aHUS, driven primarily by infusion frequency. This study contributes to the emerging real-world evidence on the treatment impact and preference in patients with aHUS.
- ||| cemdisiran (ALN-CC5) / Alnylam, Regeneron, Veopoz (pozelimab-bbfg) / Regeneron
Trial primary completion date, Combination therapy: ACCESS-1: A C5 Inhibitor-controlled Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Are Complement Inhibitor Treatment-Naive or Have Not Recently Received Complement Inhibitor Therapy (clinicaltrials.gov) - Jul 28, 2023
P3, N=190, Recruiting, Sponsor: Regeneron Pharmaceuticals
This study contributes to the emerging real-world evidence on the treatment impact and preference in patients with aHUS. Trial primary completion date: Mar 2026 --> Mar 2027
- || Soliris (eculizumab) / AstraZeneca
Enrollment closed: A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder (clinicaltrials.gov) - Jul 27, 2023
P2/3, N=12, Active, not recruiting, Sponsor: Alexion
Trial primary completion date: Mar 2026 --> Mar 2027 Recruiting --> Active, not recruiting
- || Ultomiris IV (ravulizumab-cwvz IV) / AstraZeneca
P4 data, Journal: Interim analysis of post-marketing surveillance of ravulizumab for paroxysmal nocturnal hemoglobinuria in Japan. (Pubmed Central) - Jul 21, 2023
Recruiting --> Active, not recruiting We report safety data obtained through to December 2021 for 218 patients and effectiveness data for 194 patients (182 switched from eculizumab and 12 complement inhibitor-na
- || Soliris (eculizumab) / AstraZeneca
P4 data, Journal: Long-term safety and effectiveness of eculizumab in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: a 2-year interim analysis of post-marketing surveillance in Japan. (Pubmed Central) - Jul 13, 2023
P3
This article reports interim PMS data for Japanese patients and provides updated real-world evidence for the safety of eculizumab and its effectiveness at preventing relapses in patients with AQP4+ NMOSD. Safety and effectiveness results are consistent with those from PREVENT.
- || Soliris (eculizumab) / AstraZeneca
Enrollment open: Soliris: Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in China (clinicaltrials.gov) - Jul 12, 2023
P3, N=25, Recruiting, Sponsor: Alexion
Safety and effectiveness results are consistent with those from PREVENT. Not yet recruiting --> Recruiting
- | Actemra IV (tocilizumab) / Roche, JW Pharma, Soliris (eculizumab) / AstraZeneca, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Journal, IO biomarker: Inpatient care of neuromyelitis optica spectrum disorder in Germany: Nationwide analysis from 2010 to 2021. (Pubmed Central) - Jul 12, 2023
In parallel with the administration of highly effective therapies rate of apheresis therapies decreased. A stable apheresis rate over the year makes seasonal variations of the steroid-refractive relapses unlikely.
- | Soliris (eculizumab) / AstraZeneca
Journal: Clinically important change for the FACIT-Fatigue scale in paroxysmal nocturnal hemoglobinuria: a derivation from international PNH registry patient data. (Pubmed Central) - Jul 9, 2023
A stable apheresis rate over the year makes seasonal variations of the steroid-refractive relapses unlikely. These results support the use of 5 points as the CIC for FACIT-Fatigue in patients with PNH, which is within range of the CICs reported in other diseases (3-5 points).
- | Soliris (eculizumab) / AstraZeneca, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Preclinical, Journal: Anti-complement 5 antibody ameliorates antibody-mediated rejection after liver transplantation in rats. (Pubmed Central) - Jul 7, 2023
Antibody-mediated rejection (AMR) remains a refractory rejection after donor-specific antibody (DSA)-positive or blood-type incompatible liver transplantation (LT), even in the era of pre-transplant rituximab desensitization...Notably, just two doses of Anti-C5 only on PTD-0 and -3 significantly improved biliary injury and liver fibrosis up to PTD-100, leading to better long-term animal survival (P =0.02). We newly developed a rat model of LT-AMR that meets all the Banff diagnostic criteria and demonstrated the efficacy of Anti-C5 antibody for LT-AMR.
- || Soliris (eculizumab) / AstraZeneca, Ultomiris IV (ravulizumab-cwvz IV) / AstraZeneca
Clinical data, Journal, HEOR: Atypical Hemolytic Uremic Syndrome Treated With Ravulizumab or Eculizumab: A Claims-Based Evaluation of Health Care Resource Utilization and Clinical Outcomes in the United States. (Pubmed Central) - Jul 7, 2023
Low patient numbers receiving ravulizumab only. The health-insurance claims data showed a reduced health care burden for US adult patients after treatment with ravulizumab or eculizumab for treatment of aHUS.
- | Soliris (eculizumab) / AstraZeneca
Journal, HEOR: Eculizumab for paroxysmal nocturnal haemoglobinuria: catastrophic health expenditure in Nepalese patients. (Pubmed Central) - Jul 5, 2023
Eculizumab is a terminal complement inhibitor that blocks this complement activation and has revolutionized the treatment of PNH but comes with an enormous price which can have catastrophic health expenditure in low-middle income countries (LMIC) like Nepal. Here, we discuss the potential way forwards in the treatment of PNH in Nepal and other LMICs.
- || Soliris (eculizumab) / AstraZeneca, Empaveli (pegcetacoplan SC) / Apellis, SOBI
Review, Journal: Treatment of eculizumab refractory paroxysmal nocturnal hemoglobinuria: A systematic review about current treatment options and future direction. (Pubmed Central) - Jun 30, 2023
C5 inhibitors such as eculizumab and ravulizumab are the first-line treatment in the management of paroxysmal nocturnal hemoglobinuria (PNH)...Two studies were about pegcetacoplan, one was about danicopan, and one was about iptacopan...More studies using study designs such as randomized controlled trials comparing multiple drugs should be performed to accurately assess the different medications and aid in designing guidelines of the management of eculizumab refractory PNH. Level I.
- | Tavneos (avacopan) / Kissei, Amgen, Otsuka, Soliris (eculizumab) / AstraZeneca
Journal: C5a-licensed phagocytes drive sterilizing immunity during systemic fungal infection. (Pubmed Central) - Jun 26, 2023
Lower serum C5a concentrations or a C5 polymorphism that decreases leukocyte C5 expression correlated independently with poor patient outcomes. Thus, local, phagocyte-derived C5 production licenses phagocyte antimicrobial function and confers innate protection during systemic fungal infection.
- | Soliris (eculizumab) / AstraZeneca
Trial completion date, Trial primary completion date: The Use of Eculizumab in HELLP Syndrome (clinicaltrials.gov) - Jun 23, 2023
P1, N=3, Suspended, Sponsor: Johns Hopkins University
Thus, local, phagocyte-derived C5 production licenses phagocyte antimicrobial function and confers innate protection during systemic fungal infection. Trial completion date: Jun 2023 --> Sep 2023 | Trial primary completion date: May 2023 --> Aug 2023
- || Soliris (eculizumab) / AstraZeneca
Review, Journal, Post-transplantation: A 78-Year-Old Man with Chronic Kidney Disease and Monoclonal Gammopathy Who Developed Post-Transplant C3 Glomerulopathy - Recurrence or De Novo? A Case Report and Literature Review. (Pubmed Central) - Jun 21, 2023
He was treated with eculizumab during 4 weeks while the study was completed...Patients older than 50 years who are on a waiting list for kidney transplantation should have an MG detection study. The information provided to patients with MG on a waiting list for kidney transplantation should include not only the possibility of hematologic progression but also the recurrence/de novo appearance of associated kidney pathology.
- | Soliris (eculizumab) / AstraZeneca, Opdivo (nivolumab) / Ono Pharma, BMS, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Journal: Global research hotspots and frontiers of myasthenia gravis from 2002 to 2021: A bibliometric study. (Pubmed Central) - Jun 20, 2023
The study also identified pathogenesis, eculizumab, thymic epithelial cells, immune checkpoint inhibitors, thymectomy, MuSK antibodies, risk, diagnosis, and management as the current hot research topics in MG, while burst keywords like quality of life, immune-related adverse events (irAEs), rituximab, safety, nivolumab, cancer, and classification indicated the frontiers of MG research. This study effectively identifies the hotspots and frontiers of MG research, and offers valuable references for researchers interested in this area.
- | carfilzomib / Generic mfg.
Journal: Microangiopathy in multiple myeloma: a case of carfilzomib-induced secondary thrombotic microangiopathy successfully treated with plasma exchange and complement inhibition. (Pubmed Central) - Jun 20, 2023
This study effectively identifies the hotspots and frontiers of MG research, and offers valuable references for researchers interested in this area. We report a patient with suspected proteasome inhibitor-induced secondary thrombotic microangiopathy that has been successfully treated with plasma exchange and eculizumab, a monoclonal antibody targeting complement factor C5.
- || Soliris (eculizumab) / AstraZeneca
Review, Journal: Caring for two in the ICU: pharmacologic management of pregnancy-related complications. (Pubmed Central) - Jun 16, 2023
Brief descriptions of non-pharmacological (e.g., cesarean or vaginal delivery of the baby) interventions are provided. Mainstays of pharmacotherapy highlighted include oxytocin for obstetric hemorrhage, methotrexate for ectopic pregnancy, magnesium and antihypertensive agents for preeclampsia and eclampsia, eculizumab for atypical hemolytic uremic syndrome, corticosteroids and immunosuppressive agents for thrombotic thrombocytopenic purpura, diuretics, metoprolol and anticoagulation for peripartum cardiomyopathy, and pulmonary vasodilators for amniotic fluid embolism.
- ||| Soliris (eculizumab) / AstraZeneca
Eculizumab in secondary aHUS Cordero Lucia, MD 👏👏#ERA23 (Twitter) - Jun 16, 2023
- || crovalimab (RG6107) / Roche
P1/2 data, Journal: Crovalimab treatment in patients with paroxysmal nocturnal haemoglobinuria: Long-term results from the phase I/II COMPOSER trial. (Pubmed Central) - Jun 16, 2023
P1/2
Over a 3-year median treatment duration, crovalimab was well tolerated and sustained C5 inhibition was achieved. Intravascular haemolysis control, haemoglobin stabilisation and transfusion avoidance were maintained, signifying long-term crovalimab efficacy.
- | Retrospective data, Journal: High-efficacy therapies reduce clinical and radiological events more effectively than traditional treatments in neuromyelitis optica spectrum disorder. (Pubmed Central) - Jun 16, 2023
Intravascular haemolysis control, haemoglobin stabilisation and transfusion avoidance were maintained, signifying long-term crovalimab efficacy. High-efficacy treatments maximize opportunity for preventing disease advancement in newly diagnosed and established pwNMOSD.
- | Soliris (eculizumab) / AstraZeneca
Journal: The Use of Eculizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in an Academic Hematology Center. (Pubmed Central) - Jun 16, 2023
There was low risk of adverse events. Conclusion This case series elucidates the effective use of eculizumab for atypical hemolytic uremic syndromein a diverse patient population and emphasizes the need for more research in this area.
- | Soliris (eculizumab) / AstraZeneca
Journal: The Effect of Respiratory Viral Infections on Breakthrough Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria. (Pubmed Central) - Jun 14, 2023
We retrospectively analyzed 34 patients with PNH disease between 2016 and 2018, who were on eculizumab treatment and who presented with respiratory symptoms and were subsequently tested for 10 respiratory viruses (influenza A, influenza B, parainfluenza, respiratory syncytial virus, adenovirus, rhinovirus, and human metapneumovirus)...Our data indicate that respiratory virus infections pose a significant risk for BTH in PNH patients on complement inhibitor treatment, underlining the need for regular screening and close monitoring of patients with respiratory symptoms. Furthermore, it implies a higher risk for patients who are not established on complement inhibitors, suggesting the necessity for greater vigilance in these patients.